Targeting nerve cell batteries to slow Parkinson’s progression
We’re investing nearly £1 million to find a new treatment that targets energy-producing mitochondria to slow the loss of brain cells in Parkinson's.
New research puts serotonin at the heart of Parkinson’s
In a seminal research paper, published in Lancet Neurology, researchers from King’s College London have used brain scans to uncover early changes in the brain that may happen years before the symptoms of Parkinson's appear.
HYPE protein found to target alpha-synuclein
Researchers in the US have identified a protein in the brain that may reduce the spread of the toxic alpha-synuclein protein in Parkinson's.
Targeting bacteria in the gut could increase effectiveness of levodopa
New research from Harvard University suggests changes to the gut could improve how a common Parkinson’s medication works.
New molecules targeting alpha-synuclein have potential for slowing Parkinson’s
Researchers in Japan have developed molecules that could be key to slowing the progression of Parkinson’s.
Existing drugs may help the brain protect itself against Parkinson's
Researchers at King's College London have investigated the properties of over 1,000 approved drugs to identify 2 with potential for Parkinson's.
New mouse model highlights promising potential drug for slowing Parkinson’s
The results indicate that, when given early, the molecule Anle138b may restore dopamine levels and help slow or stop Parkinson’s in its tracks.
Repurposed drug enters clinical trial for Lewy body dementia
Researchers in the US have launched a clinical trial to test a drug with the potential to slow the progression of Lewy body dementia.
Test to detect early Parkinson's given FDA Breakthrough Device Designation
The biotech company Amprion have developed a test to detect the early signs of Parkinson's, before the onset of symptoms, which they hope will be ready to market in the next 18 months.